Predictors of long-term survival in pulmonary hypertension

Affiliations

¹ Department of Internal Medicine V-Pneumology and Critical Care Medicine, University Hospital of Saarland, 66421 Homburg/Saar, Germany. Electronic address: heinrike.wilkens@uks.eu.
² Department of Internal Medicine, Mission Medical Hospital, Respiratory Medicine and Cardiology, Würzburg, Germany.

Comment

Heinrike Wilkens et al. Lancet Respir Med. 2016 May.

. 2016 May;4(5):338-9.

doi: 10.1016/S2213-2600(16)30041-8. Epub 2016 Apr 8.

¹ Department of Internal Medicine V-Pneumology and Critical Care Medicine, University Hospital of Saarland, 66421 Homburg/Saar, Germany. Electronic address: heinrike.wilkens@uks.eu.
² Department of Internal Medicine, Mission Medical Hospital, Respiratory Medicine and Cardiology, Würzburg, Germany.

No abstract available

Comment on

Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Jansa P, Kim NH, Mayer E, Pulido T, Wang C, Colorado P, Fritsch A, Meier C, Nikkho S, Hoeper MM. Simonneau G, et al. Lancet Respir Med. 2016 May;4(5):372-80. doi: 10.1016/S2213-2600(16)30022-4. Epub 2016 Apr 8. Lancet Respir Med. 2016. PMID: 27067478 Clinical Trial.
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, Kilpatrick D, Langleben D, Rosenkranz S, Menezes F, Fritsch A, Nikkho S, Humbert M. Ghofrani HA, et al. Lancet Respir Med. 2016 May;4(5):361-71. doi: 10.1016/S2213-2600(16)30019-4. Epub 2016 Apr 8. Lancet Respir Med. 2016. PMID: 27067479 Clinical Trial.